# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...
- Conference Call
Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $30 to $32.
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating ...
Wells Fargo analyst Mohit Bansal maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to $30.
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
UBS analyst Colin Bristow maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $30 to $31.
Largest head-to-head randomized clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA Foundation (FSG) show...